Apogee Therapeutics, Inc.
APGE
주식 순위
#2351
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
주가
$135.07
마지막 동기화: 2026-09-04
시가총액
$8.36B
변동 (1일)
0.00%
변동 (1년)
137.21%
국가
US
거래 Apogee Therapeutics, Inc. (APGE)
카테고리
Healthcare
Apogee Therapeutics, Inc. (APGE)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 0.00
Apogee Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0.00입니다. 2023년 말 기준 P/S 비율은 0.00였습니다.
Apogee Therapeutics, Inc.의 P/S 비율 기록 (2022 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
